Clinical trials: Thymic Cancer
Diffuse Large B Cell Lymphoma (DLBCL)
A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)
This non-randomized, open label, multi-site, first-in-human, Phase 1/2 study CRC-403 will evaluate the safety and efficacy of bbT369 in subjects with relapsed and/or refractory B cell non-Hodgkin's lymphoma (NHL).
- Trial name
- NCT05169489
- Testing
- bbT369
- Where
- 4 sites in United States
- Volunteers
- 15 people
- Sponsor
- Regeneron Pharmaceuticals
Thymic Epithelial Tumor
Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence
Hyperthermic intrathoracic chemotherapy (HITOC) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction.
- Trial name
- CHOICE (NCT05446935)
- Testing
- HITOC
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Shanghai Zhongshan Hospital
Respiratory Tract Neoplasms, Thymic Neoplasms
High Dose Somatostatin Analogues in Neuroendocrine Tumors
Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg.
- Conditions
- Respiratory Tract Neoplasms, Thymic Neoplasms, Pancreatic Neoplasms, Gastrointestinal Neoplasms
- Trial name
- HIDONET (NCT00990535)
- Testing
- Octreotide-LAR
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Federico II University
Relapsed or Metastatic Thymic Cancer, First-line Treatment
Ivonescimab Combined with Chemotherapy As First-line Treatment of Relapsed or Metastatic Thymic Cancer: a Prospective, Single Arm, Phase II Trial
This study is a prospective, single arm phase II clinical trial ,aimed at exploring the efficacy and safety of the combination therapy of anti-PD-1 and VEGF bispecific antibody Ivonescimab combined with chemotherapy as first-line…
- Trial name
- iTHYM (NCT06750952)
- Testing
- Ivonescimab Combined With Chemotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
HEARTS Trial for Thoracic Cancers
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the…
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III
- Trial name
- NCT07132918
- Testing
- MRgART, LINAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer, Colorectal Cancer
Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
RATIONALE: Printed educational materials, such as the Facing Forward Series: Life After Cancer Treatment manual, may help make the transition from cancer patient to cancer survivor easier in patients who are finishing treatment…
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma
- Trial name
- NCT00372840
- Testing
- educational intervention, psychosocial assessment and care, quality-of-life assessment
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Fox Chase Cancer Center
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Thymoma and Thymic Carcinoma, Pleural Metastasis
Phase II Trial of Hypofractionated Radiotherapy Guided by Optical Surface Imaging and Fan-beam CT for Thymoma With Pleural Metastasis
This trial plans to conduct a prospective, randomized controlled phase II clinical study to explore the efficacy and safety of hypofractionated radiotherapy guided by optical surface imaging combined with FBCT in patients with…
- Trial name
- NCT07879417
- Testing
- hypofractionated radiotherapy guided by optical surface imaging and FBCT, hypofractionated radiotherapy guided by CBCT
- Volunteers
- 234 people
- Sponsor
- Sun Yat-sen University
Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
This research is being done to assess the effectiveness and safety of acalabrutinib combined with lisocabtagene maraleucel (liso-cel) for people with relapsed/refractory aggressive B-cell lymphoma.
- Conditions
- Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL, Diffuse Large B-cell Lymphoma (DLBCL)
- Trial name
- NCT05583149
- Testing
- ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Patrick C. Johnson, MD
B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth.
- Conditions
- B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma
- Trial name
- NCT04257578
- Testing
- Acalabrutinib, Axicabtagene Ciloleucel
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Washington
Thymic Carcinoma
Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)
The goal of this clinical trial is to learn the role of adjuvant chemotherapy for patients with thymic carcinoma and completed resection. The main questions it aims to answer are: 1.
- Trial name
- NCT06402708
- Testing
- Chemotherapy, Radiotherapy
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Fudan University
Thymoma and Thymic Carcinoma
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to compare the effectiveness of octreotide alone or with prednisone in treating…
- Trial name
- NCT00003283
- Testing
- octreotide acetate, prednisone
- Where
- 25 sites in United States, South Africa
- Volunteers
- 38 people
- Sponsor
- Eastern Cooperative Oncology Group
Thymic Carcinoma, Thymoma
Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma
It is an open-lable, single-arm, single-center, phase II clinical trial conducted in China, and plan to recruiting 20 patients who were progressed after first line chemotherapy or chemotherapy combined with immunotherapy.
- Trial name
- NCT06838910
- Testing
- Experimental: tislelizumab+anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Thymic Epithelial Tumors
A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor
This is a Phase II single center, open-label, single arm study in patients with advanced thymic epithelial tumors after failure of cisplatin-based combination chemotherapy.
- Trial name
- NCT02607631
- Testing
- Pembrolizumab
- Volunteers
- 33 people
- Sponsor
- Samsung Medical Center
Esophageal Carcinoma, Hypopharyngeal Carcinoma
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation…
- Conditions
- Esophageal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Lymphoma
- Trial name
- NCT02062632
- Testing
- Doxepin Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung, Mesothelioma
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
This study will determine the maximum-tolerated dose (MTD) for oral bosutinib when used in combination with pemetrexed. The MTD is the highest dose of bosutinib with pemetrexed that can be given without causing severe side…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer
- Trial name
- NCT03023319
- Testing
- Bosutinib, Pemetrexed
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Nagla Abdel Karim
Thymoma, Thymic Carcinoma
Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage
Background: Cisplatin-containing chemotherapy is the standard treatment for advanced tumors of the thymus that cannot be removed surgically.
- Trial name
- NCT00589290
- Testing
- Belinostat (PDX101)
- Where
- 2 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Peritoneal Mesothelioma, Gestational Trophoblastic Tumor
IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Immune checkpoint inhibitors (ICI) have revolutionized the management of advanced cancers. However, most rare cancers have been excluded from this progress due to the lack of clinical trials involving these diseases.
- Conditions
- Peritoneal Mesothelioma, Gestational Trophoblastic Tumor, Anaplastic Thyroid Carcinomas, Gastroenteropancreatic Neuroendocrine Tumor
- Trial name
- IMMUNORARE5 (NCT06790706)
- Testing
- DOMVANALIMAB + ZIMBERELIMAB, DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4
- Where
- 15 sites in France
- Volunteers
- 27 people
- Sponsor
- Hospices Civils de Lyon
Thymoma, Thymic Carcinoma
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
Background: Tumors of the thymus are rare and can be treated with surgery, but it is often difficult to determine whether a thymic tumor is malignant based on biopsy alone and the long-term survival rate is less than 50 percent.
- Trial name
- NCT01100944
- Testing
- PXD101with cisplatin+doxorubicin+cyclophosphamide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)